Literature DB >> 9214219

[In vitro study with techniques of imaging of the composition of urinary calculi].

M Tellez Martínez-Fornés1, F J Burgos Revilla, J C Sáez Garrido, J Soria Descalzo, J Barbero González, J Sánchez Corral, A Minaya Minaya, J Vallejo Herrador.   

Abstract

Pre-treatment knowledge of the lithiasic composition can be useful to design the most appropriate therapeutic scheme for each kind of stone. The relationship between the stone's densitometry information provided by the different imaging techniques, conventional radiology (RX), computerized axial tomography (CAT) and dual energy radiographic densitometry (DO) is analyzed, as well as the elemental composition determined by the microanalysis of fragments obtained post-lithotrity using a scanning electronic microscope (SEM) associated to X-ray dispersion energy (XDE). 60 stones, 12 for each pure composition selected (calcium oxalate mono and dihydro, phosphocarbonate, magnesium ammonium phosphate and uric acid), were studied with XR, CAT and DO and were later subjected to lithofragmentation in vitro. Fragments analysis was carried out post-lithotrity with SEM associated to XDE. The X-ray does not allow to establish the composition of some calculi. CAT quantifies the mineral contents of the oxalocalcic and infective calculi and differentiates the uric acid from the other compositions because the mean density values are under 500 Hounsfield Units. DO evaluates the lithiasic content in phosphocarbonate salts which are structurally similar to bone hydroxyapatite.

Entities:  

Mesh:

Year:  1997        PMID: 9214219

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  1 in total

1.  Helical CT evaluation of the chemical composition of urinary tract calculi with a discriminant analysis of CT-attenuation values and density.

Authors:  Marie-France Bellin; Raphaëlle Renard-Penna; Pierre Conort; Anne Bissery; Jean-Baptiste Meric; Michel Daudon; Alain Mallet; François Richard; Philippe Grenier
Journal:  Eur Radiol       Date:  2004-06-25       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.